SAGE logo

Sage Therapeutics (SAGE) EBITDA

annual EBITDA:

-$409.49M+$135.59M(+24.87%)
December 31, 2024

Summary

  • As of today (June 19, 2025), SAGE annual EBITDA is -$409.49 million, with the most recent change of +$135.59 million (+24.87%) on December 31, 2024.
  • During the last 3 years, SAGE annual EBITDA has risen by +$47.24 million (+10.34%).
  • SAGE annual EBITDA is now -165.35% below its all-time high of $626.60 million, reached on December 31, 2020.

Performance

1-year change

+24.87%

3-year change

+10.34%

5-year change

+41.99%

15-year change

-50.2%

SAGE EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

2.9%
SAGE annual EBITDA is higher than 2.9% of companies in Healthcare sector

Range

All-time high

$626.60M
SAGE annual EBITDA is currently -165.35% below its historical high of $626.60 million

3-year low

-$545.87M

Earnings dates

Last annual earnings report date

Dec 31, 2024
SAGE previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
SAGE next annual earnings announcement has not yet been scheduled

OtherSAGEincome statement metrics

Annual revenue

$41.24M
SAGE annual revenue is $41.24 million

annual net income

-$400.67M
SAGE annual net profit is -$400.67 million

annual EBIT

-$410.52M
SAGE annual earnings before interest & taxes is -$410.52 million

Annual EPS

-$6.59
SAGE annual earnings per share is -$6.59

quarterly EBITDA:

-$66.83M+$13.38M(+16.68%)
March 31, 2025

Summary

  • As of today (June 19, 2025), SAGE quarterly EBITDA is -$66.83 million, with the most recent change of +$13.38 million (+16.68%) on March 31, 2025.
  • Over the past year, SAGE quarterly EBITDA has increased by +$50.51 million (+43.05%).
  • SAGE quarterly EBITDA is now -106.86% below its all-time high of $974.50 million, reached on December 31, 2020.

Performance

3-month change

+16.68%

1-year change

+43.05%

3-year change

+45.63%

5-year change

+48.97%

SAGE quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

5.67%
SAGE quarterly EBITDA is higher than 5.67% of companies in Healthcare sector

Range

All-time high

$974.50M
SAGE quarterly EBITDA is currently -106.86% below its historical high of $974.50 million

3-year low

-$177.92M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
SAGE previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Jul 31, 2025
SAGE next earnings announcement is scheduled for Jul 31, 2025

OtherSAGEincome statement metrics

Quarterly revenue

$14.06M
SAGE quarterly revenue is $14.06 million

quarterly net income

-$62.21M
SAGE quarterly net profit is -$62.21 million

quarterly EBIT

-$66.94M
SAGE quarterly earnings before interest & taxes is -$66.94 million

Quarterly EPS

-$1.01
SAGE quarterly earnings per share is -$1.01

TTM EBITDA:

-$358.98M+$50.51M(+12.33%)
March 31, 2025

Summary

  • As of today (June 19, 2025), SAGE TTM EBITDA is -$358.98 million, with the most recent change of +$50.51 million (+12.33%) on March 31, 2025.
  • Over the past year, SAGE TTM EBITDA has increased by +$148.29 million (+29.23%).
  • SAGE TTM EBITDA is now -153.87% below its all-time high of $666.40 million, reached on June 30, 2021.

Performance

3-month change

+12.33%

1-year change

+29.23%

3-year change

+26.09%

5-year change

+46.21%

SAGE TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

3.98%
SAGE TTM EBITDA is higher than 3.98% of companies in Healthcare sector

Range

All-time high

$666.40M
SAGE TTM EBITDA is currently -153.87% below its historical high of $666.40 million

3-year low

-$656.80M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
SAGE previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Jul 31, 2025
SAGE next earnings announcement is scheduled for Jul 31, 2025

OtherSAGEincome statement metrics

TTM revenue

$47.40M
SAGE TTM revenue is $47.40 million

TTM net income

-$354.40M
SAGE TTM net profit is -$354.40 million

TTM EBIT

-$359.78M
SAGE TTM earnings before interest & taxes is -$359.78 million

TTM EPS

-$5.80
SAGE TTM earnings per share is -$5.80

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$409.49M
SAGE annual EBITDA is -$409.49 million

annual net income

-$400.67M
SAGE annual net profit is -$400.67 million

annual interest expense

-
SAGE annual interest expense value is unknown

annual income tax

-
SAGE annual income tax value is unknown

annual D&A

$1.03M
SAGE annual depreciation & amortization is $1.03 million

SAGE EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+24.9%+43.0%+29.2%
3 y3 years+10.3%+45.6%+26.1%
5 y5 years+42.0%+49.0%+46.2%

SAGE EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+25.0%-59.6%+62.4%at high+45.3%
5 y5-year-165.3%+42.0%-106.9%+62.4%-153.9%+46.2%
alltimeall time-165.3%+42.0%-106.9%+64.2%-153.9%+49.1%

SAGE EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$66.83M(-16.7%)
-$358.98M(-12.3%)
Dec 2024
-$409.49M(-24.9%)
-$80.21M(-20.5%)
-$409.49M(+10.3%)
Sep 2024
-
-$100.95M(-9.0%)
-$371.15M(-17.2%)
Jun 2024
-
-$110.99M(-5.4%)
-$448.13M(-11.7%)
Mar 2024
-
-$117.34M(+180.2%)
-$507.26M(-6.9%)
Dec 2023
-$545.07M(-0.1%)
-$41.88M(-76.5%)
-$545.07M(-17.0%)
Sep 2023
-
-$177.92M(+4.6%)
-$656.80M(+5.9%)
Jun 2023
-
-$170.13M(+9.7%)
-$620.09M(+7.3%)
Mar 2023
-
-$155.15M(+1.0%)
-$578.12M(+5.9%)
Dec 2022
-$545.87M(+19.5%)
-$153.61M(+8.8%)
-$545.90M(+5.5%)
Sep 2022
-
-$141.20M(+10.2%)
-$517.44M(+2.1%)
Jun 2022
-
-$128.16M(+4.3%)
-$506.76M(+4.3%)
Mar 2022
-
-$122.92M(-1.8%)
-$485.73M(+6.3%)
Dec 2021
-$456.73M(-172.9%)
-$125.15M(-4.1%)
-$456.73M(-171.0%)
Sep 2021
-
-$130.52M(+21.8%)
$642.92M(-3.5%)
Jun 2021
-
-$107.13M(+14.1%)
$666.40M(+0.4%)
Mar 2021
-
-$93.92M(-109.6%)
$663.63M(+5.9%)
Dec 2020
$626.60M(-188.8%)
$974.50M(-1010.4%)
$626.60M(-220.1%)
Sep 2020
-
-$107.04M(-2.6%)
-$521.87M(-13.2%)
Jun 2020
-
-$109.90M(-16.1%)
-$601.31M(-9.9%)
Mar 2020
-
-$130.96M(-24.7%)
-$667.36M(-5.5%)
Dec 2019
-$705.84M(+80.0%)
-$173.97M(-6.7%)
-$705.84M(+1.5%)
Sep 2019
-
-$186.48M(+6.0%)
-$695.73M(+9.1%)
Jun 2019
-
-$175.95M(+3.8%)
-$637.71M(+31.9%)
Mar 2019
-
-$169.44M(+3.4%)
-$483.66M(+23.4%)
DateAnnualQuarterlyTTM
Dec 2018
-$392.10M(+43.8%)
-$163.86M(+27.6%)
-$392.10M(+31.3%)
Sep 2018
-
-$128.46M(+486.5%)
-$298.55M(+22.2%)
Jun 2018
-
-$21.90M(-71.9%)
-$244.32M(-16.7%)
Mar 2018
-
-$77.87M(+10.7%)
-$293.15M(+7.5%)
Dec 2017
-$272.62M(+70.5%)
-$70.31M(-5.3%)
-$272.63M(+5.4%)
Sep 2017
-
-$74.24M(+5.0%)
-$258.61M(+16.3%)
Jun 2017
-
-$70.72M(+23.3%)
-$222.35M(+19.2%)
Mar 2017
-
-$57.35M(+1.9%)
-$186.56M(+16.7%)
Dec 2016
-$159.88M(+69.1%)
-$56.30M(+48.2%)
-$159.88M(+21.0%)
Sep 2016
-
-$37.98M(+8.7%)
-$132.16M(+11.8%)
Jun 2016
-
-$34.93M(+13.9%)
-$118.24M(+9.1%)
Mar 2016
-
-$30.67M(+7.3%)
-$108.33M(+14.6%)
Dec 2015
-$94.53M(+180.0%)
-$28.58M(+18.8%)
-$94.53M(+20.7%)
Sep 2015
-
-$24.05M(-3.9%)
-$78.30M(+22.9%)
Jun 2015
-
-$25.03M(+48.3%)
-$63.70M(+42.0%)
Mar 2015
-
-$16.88M(+36.7%)
-$44.85M(+32.9%)
Dec 2014
-$33.76M(+85.2%)
-$12.35M(+30.5%)
-$33.76M(+24.5%)
Sep 2014
-
-$9.46M(+53.1%)
-$27.11M(+22.3%)
Jun 2014
-
-$6.18M(+6.9%)
-$22.17M(+7.4%)
Mar 2014
-
-$5.78M(+1.4%)
-$20.63M(+13.2%)
Dec 2013
-$18.23M(+90.2%)
-$5.70M(+26.5%)
-$18.23M(+45.5%)
Sep 2013
-
-$4.51M(-2.9%)
-$12.53M(+56.2%)
Jun 2013
-
-$4.64M(+37.4%)
-$8.02M(+137.4%)
Mar 2013
-
-$3.38M
-$3.38M
Dec 2012
-$9.59M
-
-

FAQ

  • What is Sage Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Sage Therapeutics?
  • What is Sage Therapeutics annual EBITDA year-on-year change?
  • What is Sage Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Sage Therapeutics?
  • What is Sage Therapeutics quarterly EBITDA year-on-year change?
  • What is Sage Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Sage Therapeutics?
  • What is Sage Therapeutics TTM EBITDA year-on-year change?

What is Sage Therapeutics annual EBITDA?

The current annual EBITDA of SAGE is -$409.49M

What is the all time high annual EBITDA for Sage Therapeutics?

Sage Therapeutics all-time high annual EBITDA is $626.60M

What is Sage Therapeutics annual EBITDA year-on-year change?

Over the past year, SAGE annual EBITDA has changed by +$135.59M (+24.87%)

What is Sage Therapeutics quarterly EBITDA?

The current quarterly EBITDA of SAGE is -$66.83M

What is the all time high quarterly EBITDA for Sage Therapeutics?

Sage Therapeutics all-time high quarterly EBITDA is $974.50M

What is Sage Therapeutics quarterly EBITDA year-on-year change?

Over the past year, SAGE quarterly EBITDA has changed by +$50.51M (+43.05%)

What is Sage Therapeutics TTM EBITDA?

The current TTM EBITDA of SAGE is -$358.98M

What is the all time high TTM EBITDA for Sage Therapeutics?

Sage Therapeutics all-time high TTM EBITDA is $666.40M

What is Sage Therapeutics TTM EBITDA year-on-year change?

Over the past year, SAGE TTM EBITDA has changed by +$148.29M (+29.23%)
On this page